Begin the 30,000-participant Phase 3 COVE study of mRNA-1273

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 15 Jul 2020
Due: 27 Jul 2020
Delivered: 27 Jul 2020

Deadline
Met
Late
Not met
Today

What the company said

“Data support 30,000 participant Phase 3 study expected to begin on July 27”

SourceModerna Form 8-K press release, 2020-07-15
FilingSEC filing index
Deadline as statedto begin on July 27
Deadline used27 Jul 2020, the last day of the stated period
TypeProject
Permanent referenceKI-C-2020-MRNA-006143
Cite as https://keptindex.org/c/KI-C-2020-MRNA-006143/ — this address never changes.

What we found

Evidence strength A What the grades mean

Later filings state the Phase 3 COVE study began, with enrollment starting, on July 27, 2020, matching the stated deadline.

A
Moderna 8-K filed 2020-07-29 Regulatory filing · published 29 Jul 2020 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint 8632ad5d39c0
“On July 27, the Phase 3 COVE study of mRNA-1273, being conducted in collaboration with NIH and BARDA, began.” ✓ confirmed on the page
A
Moderna 10-Q filed 2020-08-06 Regulatory filing · published 6 Aug 2020 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint 8e57406eaeba
“which began enrollment on July 27, 2020.” ✓ confirmed on the page

Market reaction: the shares moved -10.7% against the S&P 500 over the three sessions around the disclosure (28 Jul 2020 to 31 Jul 2020). What this measures

Checked 10 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +65 days
2 versions

Version 1 · original · stated 15 Jul 2020

Deadline 27 Jul 2020 (“to begin on July 27”) · target 30,000 participants · wording expected
Version 2 · stated 12 Aug 2020

Deadline 30 Sep 2020 (“in September”) · wording firm

“The Phase 3 COVE study of mRNA-1273, being conducted in collaboration with the NIH and BARDA, began on July 27; enrollment is on track to complete in September.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Begin
Deliverable: Phase 3 COVE study of mRNA-1273
Target: 30,000 participants
Where: U.S.
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High
Depends on: Regulatory

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.